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Kevin E. Kip, PHD,* Kim Hollabaugh, RN, MSN,† Oscar C. Marroquin, MD, FACC,‡
David O. Williams, MD, FACC§
Tampa, Florida; Pittsburgh, Pennsylvania; and Providence, Rhode Island
Objectives Our purpose was to evaluate the heterogeneity and validity of composite end points, major adverse cardiac
events (MACE) in particular, in cardiology research.
Background The term MACE is a commonly used end point for cardiovascular research. By definition, MACE is a composite of
clinical events and usually includes end points reflecting safety and effectiveness. There is no standard definition
for MACE, as individual outcomes used to make this composite end point vary by study. This inconsistency calls
into question whether use of MACE in cardiology research is of value.
Methods We conducted a 2-phase literature review on the use of MACE as a composite end point: 1) studies that have
compared use of bare-metal versus drug-eluting stents; and 2) studies published in the Journal in calendar year
2006. We subsequently tested 3 different definitions of MACE during 1-year of follow-up among 6,922 patients
in the DEScover registry who received at least 1 drug-eluting stent.
Results The review identified substantial heterogeneity in the study-specific individual outcomes used to define MACE.
Markedly different results were observed for selected patient subsets of acute myocardial infarction (MI) (vs. no
MI) and multilesion stenting (vs. single-lesion stenting) according to the various definitions of MACE.
Conclusions Varying definitions of composite end points, such as MACE, can lead to substantially different results and conclu-
sions. Therefore, the term MACE, in particular, should not be used, and when composite study end points are
desired, researchers should focus separately on safety and effectiveness outcomes, and construct separate com-
posite end points to match these different clinical goals. (J Am Coll Cardiol 2008;51:701–7) © 2008 by the
American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.10.034p
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ahe term MACE, defined as “major adverse cardiac events,”
s arguably the most commonly used composite end point in
ardiovascular research. Historically, the term MACE ap-
ears to have originated in the mid-1990s with its use
estricted primarily to in-hospital complications related to
ercutaneous coronary interventions (PCIs) (1,2). Today,
owever, even though there is no standard definition of
ACE, it is routinely used and reported for procedural,
hort-term, and long-term outcome evaluations, and may
nvolve other cardiovascular treatments.
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ardiology, Rhode Island Hospital, Providence, Rhode Island. Supported, in part, by
ordis Corporation (a Johnson & Johnson Company). Drs. Kip and Williams have
eceived research support from Cordis Corporation, and Drs. Williams and Marro-
uin have served as consultants for Cordis Corporation.t
Manuscript received May 2, 2007; revised manuscript received September 4, 2007,
ccepted October 29, 2007.By definition, MACE, as well as all other composite end
oints, include multiple types of clinical events of varying
egrees of relatedness. At the broadest level, definitions of
ACE in use today include end points that reflect both the
afety and effectiveness of various treatment approaches. This
pparent mixing of “apples and oranges” and inconsistency
alls into question whether use of MACE is of value. The
urpose of this study was to evaluate the validity and utility
f MACE as a composite research study end point, with the
orresponding results presumably applicable to composite
nd points at large.
ethods
o evaluate the usefulness of MACE as an end point, we
onducted a literature review followed by an empirical
nalysis. The literature review was performed to determine
he heterogeneity of MACE. The empirical analysis tested
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Composite End Points in Cardiology Studies February 19, 2008:701–7the influence of different defini-
tions on the interpretation of
clinical investigations.
Literature review and data ab-
straction. We arbitrarily con-
sidered, a priori, 2 unrelated ap-
proaches of inquiry. In the first
approach, we sought to query
clinical trials that addressed a
timely and relevant research
question. We identified random-
ized clinical trials (RCTs) that
have compared the use of drug-
eluting stents (DES) to bare-
metal stents (BMS) in PCI, and
have reported MACE as either a
primary or secondary end point.
To achieve this, we searched the
MEDLINE and Cochrane Cen-
tral Register of Controlled Trials
databases using the medical
erms: bare-metal stents, drug-eluting stents, sirolimus, everoli-
us, rapamycin, paclitaxel, taxane, and taxol for calendar
ears 2002 to 2007. We then used the search terms MACE,
ajor adverse cardiac events, or major clinical adverse events
or the same years. We combined the searches with the limit
erm of clinical trial. We eliminated any report that did not
escribe primary trial results. Additionally, the bibliogra-
hies of the selected papers were reviewed along with those
f several meta-analyses and pooled analysis articles for
elevant trials (3–9). A total of 20 RCTs comparing any
ES and BMS and reporting MACE as an end point were
dentified (10–29).
In the second approach, we sought to investigate the use
f MACE at large (i.e., irrespective of a specific research
uestion). Thus, we searched the MEDLINE database
sing the terms MACE, major adverse cardiac events, or
ajor clinical adverse event. For practical reasons, we re-
tricted this search to the Journal (J Am Coll Cardiol) for
alendar year 2006. This resulted in the identification of 27
rticles (23,29–54).
For each review, the individual outcomes that made up
he definition of MACE were identified and abstracted
ndependently by 2 reviewers (K.K., K.H.). Reviewer dis-
repancies in the individual outcomes of MACE were
esolved by consensus.
mpirical analysis. Based on the results of the literature
eview, we constructed 3 definitions of MACE relevant to
he setting of PCI. Included was a definition postulated to
elate primarily to safety (death, myocardial infarction [MI],
r stent thrombosis [ST]), and 2 definitions postulated to
elate to both safety and effectiveness: 1) death, MI, ST, or
arget vessel revascularization (TVR); and 2) death, MI, ST,
r any repeat revascularization).
Using the various constructed definitions, we evaluated
Abbreviations
and Acronyms
ARC  Academic Research
Consortium
BMS  bare-metal stent(s)
CI  confidence interval
DES  drug-eluting stent(s)
MACE  major adverse
cardiac events
MI  myocardial infarction
PCI  percutaneous
coronary intervention
RCT  randomized clinical
trial
ST  stent thrombosis
TLR  target lesion
revascularization
TVR  target vessel
revascularization-year risk of MACE in the DEScover registry (55). Briefly, tEScover is a prospective, multicenter, observational study
esigned to characterize PCI patients from a broad sam-
ling of 140 hospitals across the U.S. The only exclusion
riteria were patient refusal or inability to provide written
nformed consent and/or Health Insurance Portability and
ccountability Act of 1996 authorization. Baseline clinical
nd angiographic characteristics and procedural and clinical
n-hospital events were recorded for the enrolled patients.
ollow-up was obtained from patients at 1, 6, and 12
onths by a central telephone facility. For those patients
eporting an event, a specially trained research coordinator
hen obtained additional information.
The present investigation was restricted to the 6,922
atients in DEScover who received at least 1 DES and did
ot initially present with cardiogenic shock. We assessed
ariation in 1-year risk of MACE using the different
efinitions and 2 types of patient subset comparisons. In the
rst type, we sought to compare patient subsets at increased
isk for adverse events. In this scenario, we were interested
n the influence of various definitions in regard to long-term
afety, but not necessarily effectiveness. Thus, we selected and
ompared patients presenting with versus without acute MI.
or the second subgroup analysis, we sought to compare
efinitions among patient subsets who might be at greater
isk for lesion recurrence. This analysis would assess the
mpact of definitions on long-term effectiveness, but not
ecessarily safety. Thus, we selected and compared patients
ith multiple versus 1 lesion treated with PCI. We had
nitially considered comparing patients treated with BMS
ersus DES, but in DEScover, only 5% of patients received
MS and their baseline characteristics are very different
i.e., potential selection bias) from those who received DES.
For each comparison, adjusted hazard ratios were esti-
ated by use of Cox proportional hazards regression.
ovariates adjusted for included age, gender, urgent or
mergent presentation, smoking status, number of diseased
essels, and history of diabetes, congestive heart failure,
eripheral vascular disease, renal dysfunction or dialysis, or
ulmonary disease. Analyses were performed using the SAS
ystem version 9.0 (SAS Institute, Cary, North Carolina).
esults
iterature review and data abstraction. As seen in Table 1
n the RCTs that have compared DES with BMS, all
ncluded death as a component of MACE; however, the
alance between the use of all-cause mortality versus
ardiac-only mortality was about equal. In addition, MI was
ncluded as part of MACE in all trials with only 1 trial
estricting the definition to Q-wave MI. For the remaining
omponents of MACE, the trials were variable with a
inority including ST, all including either target lesion
evascularization (TLR) or TVR, and a few including
oronary artery bypass grafting or stroke. Thus, even with a
ery specific research question (DES vs. BMS), it is clear
hat there was no consensus definition of MACE.
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February 19, 2008:701–7 Composite End Points in Cardiology StudiesIn the review of publications in the Journal for calendar
ear 2006, the results were more variable (Table 2). Like the
CT review, death and MI were included in all definitions
f MACE, although in the Journal review, nearly all
ncluded all-cause mortality rather than cardiac-only mor-
ality. The remaining components of MACE were highly
ariable, with most including a repeat revascularization
omponent (e.g., TLR, TVR) and a range of other out-
omes including stroke, acute coronary syndrome, restenosis
n angiographic follow-up evaluation, and congestive heart
CTs of BMS Versus DES With MACE as an Outcome
Table 1 RCTs of BMS Versus DES With MACE as an Outcome
Reference Year (Ref. #)
Journal Trial Name
Composite
Name Death
C
D
Morice et al. 2002 (11)
N Engl J Med
RAVEL MACE, P ✓
Grube et al. 2003 (12)
Circulation
TAXUS-I MACE, P ✓
Colombo et al. 2003 (13)
Circulation
TAXUS-II MACE, S
Moses et al. 2003 (14)
N Engl J Med
SIRIUS MACE P & S ✓ S
Schofer et al. 2003 (10)
Lancet
E-SIRIUS MACE, S ✓
Ardissino et al. 2004 (15)
JAMA
SES-SMART MACE and
CVA, S
Gershlick et al. 2004 (16)
Circulation
ELUTES MACE, S ✓
Grube et al. 2004 (17)
J Am Coll Cardiol
SCORE MACE, S
Grube et al. 2004 (18)
Circulation
FUTURE I MACE, P ✓
Lansky et al. 2004 (19)
Circulation
DELIVER Composite, P ✓
Schampaert et al. 2004 (20)
J Am Coll Cardiol
C-SIRUS MACE, S ✓
Stone et al. 2004 (21)
N Engl J Med
TAXUS-IV MACE, P
Kaiser et al. 2005 (22)
Lancet
BASKET Cost
Effectiveness
MACE, P
Kelbaek et al. 2006 (23)
J Am Coll Cardiol
SCANDSTENT MACE, S ✓
Sabate et al. 2005 (24)
Circulation
DIABETES MACE, S
Stone et al. 2005 (25)
JAMA
TAXUS-V MACE, S
Fajadet et al. 2006 (26)
Circulation
ENDEAVOR-II Composite
MACE, S
✓ S
Suttorp et al. 2006 (27)
Circulation
PRISON-II MACE, S
Tsuchiya et al. 2006 (28)
J Am Coll Cardiol
FUTURE-I FUTURE-II
(pooled)
MACE, P
Vermeersch et al. 2006 (29)
J Am Coll Cardiol
RRISC MACE, S ✓
ASKET  Basel Stent Cost-Effectiveness Trial; BMS  bare-metal stent; CABG  coronary artery
oronary Lesions; CVA cardiovascular accident; DES drug-eluting stent; DIABETES A Prospec
n Patients With Diabetes Mellitus; ELUTES European evaLUation of pacliTaxel Eluting Stent; END
or Coronary Revascularization; E-SIRIUS  European Sirolimus-Eluting Stent in Coronary Lesions
valuation of the Biosbsorbable Polymer-based Everolimus-Eluting Stent; MACE  major advers
andomized Trial of Sirolimus-Eluting and Bare Metal Stents in Patients With Chronic Total Occlusio
ith a Standard Stent for Coronary Revascularization; RCT  randomized clinical trial; RRISC 
iseased saphenous vein grafts; S “secondary” study outcome; SCANDSTENT Stenting of Coron
ueST and QuaDDS-QP2; SES-SMART  Sirolimus-Eluting Stent and a Standard Stent in the Preve
stent thrombosis; TLR  target lesion revascularization; TVR  target vessel revascularization;ailure hospitalization. Thus, in the absence of a specific research question (i.e., DES vs. BMS), the definition of
ACE was even more heterogeneous.
mpirical investigation. For the 3 constructed defini-
ions of MACE, the numbers of incident events during
-year follow-up in the DEScover registry were as
ollows: 1) death, MI, or ST (362 events); 2) death, MI,
T, or TVR (674 events); and 3) death, MI, ST, or any
epeat revascularization (868 events). Thus, when TVR
as added to the safety end point of death, MI, or ST, the
umber of incident events nearly doubled. When any
MI
Q-Wave
MI ST TLR TVR
CABG
(Emergent) CABG Stroke
✓ ✓ ✓
✓ ✓ ✓
✓ ✓
✓ P ✓ S ✓ S ✓ P
✓ ✓ ✓
✓ ✓ ✓ ✓
✓ ✓ ✓
✓ ✓
✓ ✓ within
30 days
✓ TVR
✓ ✓
✓ ✓ ✓
✓ ✓
✓ ✓
✓ ✓
✓ ✓ ✓
✓ ✓
✓ P ✓ S ✓ S ✓ P ✓ S
✓ ✓
✓ ✓ ✓ TVR
✓ ✓
s graft surgery; Cost effect.  cost-effectiveness; C-SIRUS  Canadian Sirolimus-Eluting Stent in
ndomized, Controlled Trial of the Polymer-Based, Sirolimus-Eluting Stent Versus a Bare Metal Stent
II Randomized Comparison of the Endeavor ABT-578 Drug Eluting Stent With a Bare Metal Stent
E I  First Use To Underscore Restenosis Reduction with Everolimus; FUTURE II  Multicenter
ac event; MI  myocardial infarction; P  “primary” study outcome; PRISON II  Prospective
I Q-wavemyocardial infarction; RAVEL A Randomized Comparison of a Sirolimus-Eluting Stent
ized double-blind comparison of sirolimus-eluting stent versus bare-metal stent implantation in
ries in Non-Stress/Benestent Disease Trial; SCORE Study to COmpare REstenosis Rate between
f Restenosis in Small Coronary Arteries; SIRIUS  Sirolimus-Eluting Stent in Coronary Lesions; ST
ithin.ardiac
eath
✓
✓ P
✓
✓
✓
✓
✓
✓
✓ P
✓
✓
bypas
tive, Ra
EAVOR
; FUTUR
e cardi
ns; Q-M
Random
ary Arteepeat revascularization was added to the safety definition
Use of the Term MACE as an Outcome in the Journal (2006)
Table 2 Use of the Term MACE as an Outcome in the Journal (2006)
Reference Trial Name/Description Composite Name Death
Cardiac
Death MI
Q-Wave
MI ST TLR TVR
CABG
(Emergent) CABG Stroke Other
Alfonso et al. (30) RIBS-II Any major event ✓ ✓ ✓
Ali et al. (31) AIMI rheolytic thrombectomy/PCI/infarct size MACE, S ✓ ✓ ✓ ✓ ✓ ✓
Beyar et al. (32) Remote-Control PCI MACE ✓ ✓ Urgent revascularization
Cosgrave et al. (33) Drug-eluting stent restenosis MACE, S ✓ ✓
Elezi et al. (34) Cost analyses SES versus PES MACE ✓ ✓ ✓ PCI or CABG
Engelmann et al. (35) Stem cell mobilization after MI MACE ✓ Repeat ✓ ACS
Gupta et al. (36) Hemodynamic depression after carotid stenting MACE ✓ ✓ ✓
Hochholzer et al. (37) EXCELSIOR Platelet inhibition and clopidogrel
and coronary stent
MACE, P ✓ ✓ ✓ Urgent
Hoye et al. (38) Long-term DES outcomes with crush MACE ✓ ✓ AMI ✓
Kandzari et al. (39) ENDEAVOR III Comparison of ZES versus SES MACE, S ✓ ✓ ✓
Kelbaek et al. (23) SCANDSTENT MACE, S ✓ ✓ ✓
Kereiakes et al. (40) Overlapping SES MACE ✓ ✓ ✓
Kim et al. (41) RCT–Korea Abciximab-coated versus BMS MACE, P ✓ ✓ ✓
Knopf et al. (42) Summit PROGRESS-AMS trial MACE ✓ ✓ ✓
Lee et al. (43) Comparison of CABG with PCI with DES MACE & CVA events ✓ ✓ ✓ ✓
Liistro et al. (44) TRUE registry; effect/safety of SES for in-stent
restenosis
MACE ✓ ✓ ✓
McClean et al. (45) Vascular disease HTN and prevention MACE ✓ ✓
Montalescot et al. (46) ALBION RCT high clopidogrel dose in NST ACS MACE, S ✓ ✓ Ischemia-driven
hospitalization PCI or
CABG
Moses et al. (47) DES in intermediate lesions; pooled analysis MACE ✓ ✓ ✓ ✓ Restenosis on
angiography
Ong et al. (48) RESEARCH registry, 2-year follow-up MACE ✓ ✓ ✓
Price et al. (49) Angiographic follow-up in SES MACE ✓ ✓ ✓ ✓
Rodriguez et al. (50) ORAR II study; oral rapamycin after BMS MACE, S ✓ ✓ ✓ ✓
Saia et al. (51) REAL registry PES versus SES MACE, P ✓ ✓ ✓
Sato et al. (52) Serum tenascin-C as predictor of LV remodeling MACE ✓ ✓ AMI CHF hospitalization
Valgimigli et al. (53) Distal LM disease RESEARCH/T-SEARCH
registries
MACE, P ✓ ✓ ✓
Vermeersch et al. (29) RRISC MACE, S ✓ ✓ ✓
Weisz et al. (54) SIRUS 2-year outcomes MACE P & S ✓ S ✓ P ✓ P ✓ S ✓ P ✓ P
✓ S
ACS  acute coronary syndromes; AMI  acute myocardial infarction; AIMI  A Prospective, Randomized, Controlled Trial of Thrombectomy With the AngioJet in Acute Myocardial Infarction; ALBION  Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet
Activation, Inflammation, and On-going Necrosis; CHF  congestive heart failure; ENDEAVOR III  Randomized Comparison of Zotarolimus-Eluting and Sirolimus-Eluting Stents in Patients With Coronary Artery Disease; EXCELSIOR  Impact of Extent of Clopidogrel-Induced
Platelet Inhibition During Elective Stent Implantation on Clinical Event Rate; HTN hypertension; LM left main coronary artery; LV left ventricular; NST non–ST-segment elevation acute coronary syndrome; ORAR II Oral Treatment of Restenosis; PCI percutaneous
coronary intervention; PES  paclitaxel-eluting stent; PROGRESS-AMS  Clinical Performance and Angiographic Results in Absorbable Metal Stents; RCT  randomized clinical trial; REAL  REgistro regionale AngiopLastiche dell’Emilia-Romagna; RESEARCH 
Rapamycin-Eluting Stent Evaluated at Rotterdam Cardiology Hospital; RIBS-II  Restenosis Intrastent: Balloon Angioplasty Versus Elective Sirolimus-Eluting Stenting; SES  sirolimus-eluting stent; TRUE  Tuscany Registry of Sirolimus for Unselected In-Stent Restenosis;
T-SEARCH  Taxus-Stent Evaluated At Rotterdam Cardiology Hospital; ZES  zotarolimus-eluting stent; other abbreviations as in Table 1.
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February 19, 2008:701–7 Composite End Points in Cardiology Studiesf MACE, the number of incident events increased
.4-fold.
In the first comparison (Fig. 1, top), patients presenting
ith acute MI (vs. no acute MI) were at significantly higher
djusted risk of the safety only definition of MACE (death,
I, or ST) (adjusted hazard ratio 1.75, 95% confidence
nterval [CI] 1.31 to 2.34). In contrast, when TVR was
dded to the definition of MACE, the adjusted risk asso-
iated with the presentation of acute MI was substantially
ttenuated (diluted) and no longer statistically significant
adjusted hazard ratio 1.20, 95% CI 0.95 to 1.51). Similar
esults were observed when any repeat revascularization
ather than TLR was part of the MACE definition (ad-
usted hazard ratio 1.14, 95% CI 0.92 to 1.40).
In the second comparison (Fig. 1, bottom), the use of
ultilesion PCI versus single-lesion PCI was not signifi-
antly associated with the safety only definition of MACE
death, MI, or ST) (adjusted hazard ratio 1.06, 95% CI
.77 to 1.48). In contrast, when TVR was added to the
efinition of MACE, the adjusted hazard ratio associated
ith multilesion PCI was substantially higher and statis-
ically significant (adjusted hazard ratio 1.41, 95% CI
.13 to 1.75).
iscussion
n this analysis, we have shown that in clinical investiga-
ions, there is significant heterogeneity in the individual
utcomes used to define composite end points such as
ACE, and depending on the particular set of clinical
utcomes used, widely different results and conclusions may
e obtained even within a single study. In particular, in the
etting of PCI, when mixing outcomes presumed to relate to
Figure 1 Adjusted Hazard Ratios
for Different MACE Definitions
Adjusted hazard ratios of different definitions of major adverse cardiac events
(MACE) comparing acute myocardial infarction (MI) versus nonacute MI patients
(top) and patients with multilesion versus single-lesion percutaneous coronary
intervention (bottom). Filled center circles depict the adjusted hazard ratios,
filled circles at the left and right ends depict the lower and upper 95% confi-
dence limits. Revasc  revascularization; ST  stent thrombosis; TVR  target
vessel revascularization.dafety (i.e., death, MI, ST) with outcomes presumed to
elate to procedural effectiveness (e.g., TVR or repeat revas-
ularization at large), the influence of postulated risk factors
e.g., acute MI) and procedural strategies (e.g., multilesion
CI) may be substantially attenuated or increased. Collec-
ively, these observations warrant a reappraisal of the use of
ACE and composite end points at large.
Given the seemingly obvious heterogeneity in individual
afety and effectiveness outcomes used to construct MACE,
ne wonders why its use has become so pervasive in
ardiology research. Importantly, when the term MACE
as initially used, its purpose was to evaluate the “net effect,”
hat is, both the potential utility (effectiveness) and hazard-
usness (safety) of a new acute intervention. In that setting,
ts use was warranted in order to assess the true overall acute
ffect of a particular intervention. Unfortunately, over the
ears the use of MACE has extended to reporting of
ntermediate- and long-term outcomes in which both effec-
iveness and safety outcomes are put together, even when one
s not necessarily interested in assessing the “net effect” of a
articular intervention. Thus, this use of MACE, as shown
n our analysis, can lead to different conclusions and
nterpretations of the “effect” of a particular intervention.
A second primary reason that may explain the widespread
se of MACE in cardiology research is a general belief that
sing multiple outcomes to construct a definition of MACE
ill yield a large number of incident events that, in turn, will
ncrease statistical power to demonstrate statistical signifi-
ance. While this may occur in many circumstances, it is by
o means absolute since, as shown in our analysis, some
efinitions of MACE may substantially attenuate relative
isks (i.e., effect of acute MI), which would tend to bias
esults away from statistical significance.
A third possible reason, as stated in a recent editorial (56),
s the potential for certain sponsors to “game” their trials by
onstruction and use of a particular composite outcome. For
xample, as recently demonstrated (57), individual compo-
ent outcomes that are considered minor (e.g., nonfatal
ngina) or moderate (e.g., coronary revascularization) tend
o occur more frequently than deaths or other critical
utcomes (e.g., cardiac arrest). Therefore, an apparent positive
ffect of a particular therapy may be present primarily, or
xclusively, for only the individual outcomes that are of
esser clinical importance (57,58). By analogy, this circum-
tance was observed in our analysis of the effect of multile-
ion versus single-lesion PCI when the outcome of repeat
evascularization (i.e., lesser clinical importance and more
ommon than death, MI, or ST) was added to the definition
f MACE, and statistically significant results emerged.
The potential for misleading conclusions depending on
he study-specific definition of MACE used is not trivial.
onsider a comparison of BMS to DES in which the
efinition of MACE includes TVR; if the latter had a lower
azard ratio of having MACE, one could erroneously
onclude that DES are significantly better at reducing
eath, MI, ST, and TVR in totality, even though the
“
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Composite End Points in Cardiology Studies February 19, 2008:701–7significant” effect on MACE would likely be being driven
rimarily or solely by a reduction in TVR.
In light of the approximate prior 15 years use of the term
ACE and its wide heterogeneity in definition and re-
earch applications, it is unlikely that a consensus definition
ill either be universally desired or practical for future
esearch. Therefore, we recommend against the routine use
f MACE as a composite end point at large. However, if a
road heterogeneous composite end point such as MACE is
ltimately desired, minimally, it must be clearly defined, and
he individual as well as composite end points need to be
nalyzed, presented, and discussed. If different definitions
re used for even 1 component of the composite end point,
ates of the composite end point may vary widely. To
llustrate, in TAXUS-I (12), only Q-wave MI was included
n the definition of MACE, and there were no MIs at 30
ays or 1-year in either the TAXUS or control groups. In
ontrast, in TAXUS-V among patients with complex dis-
ase (25), the 30-day MACE rates of 5.1% and 3.6% in the
AXUS and control groups, respectively, were dominated
y the inclusion of non–Q-wave MI rates of 4.4% and 3.3%,
espectively.
Our general recommendation against the use of MACE
s consistent with that of the Academic Research Consor-
ium (ARC) (59), which has aimed to establish consensus
efinitions for both individual and composite DES study
nd points. The ARC has suggested 2 composite end points
or DES trials: a device-oriented and overall patient-oriented
nd point, whereas for cardiology studies at large (i.e., not
estricted to DES trials), we recommend focusing separately
n safety and effectiveness outcomes, and constructing sepa-
ate composite (and sample size calculations, among others)
nd points that contain well-defined internally coherent
omponents to match these different clinical entities.
eprint requests and correspondence: Dr. Kevin E. Kip, Uni-
ersity of South Florida, College of Nursing, MDC 22, Room
010, 12901 Bruce B. Downs Boulevard, Tampa, Florida 33612.
-mail: kkip@health.usf.edu.
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